(19)
(11) EP 4 824 064 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24834092.9

(22) Date of filing: 13.12.2024
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61P 35/00(2006.01)
A61K 31/4985(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 487/04; A61P 35/00; A61K 31/519
(86) International application number:
PCT/IB2024/062638
(87) International publication number:
WO 2025/126143 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 13.12.2023 WO PCT/CN2023/138508

(71) Applicant: Johnson & Johnson Enterprise Innovation Inc.
New Brunswick, NJ 08933 (US)

(72) Inventors:
  • NG, Alicia Tee Fuay
    Shanghai 200233 (CN)
  • MCQUEEN, Lisa
    2340 Beerse (BE)
  • TIEGER, Eszter
    2340 Beerse (BE)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) CRYSTALLINE FORMS OF A2A RECEPTOR ANTAGONIST, PREPARATION METHODS, AND USES THEREOF